Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nintedanib + Prednisone for Radiation Pneumonitis
NCT02496585Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jul 2015
- Primary completion
- Apr 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in radiation pneumonitis (RP) comparing Nintedanib + Prednisone with Placebo + Prednisone (2 arms). Primary endpoint: Number of Patients Who Are Free From Pulmonary Exacerbations at 12 months. Started Jul 2015; status: completed.
02
Drugs
nintedanib
03
Conditions
radiation pneumonitis (RP)
Beyond the preview
Go deeper on NCT02496585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02496585.